News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dipexium (DPRX) Reports Third Quarter 2016 Financial Results



11/11/2016 1:29:32 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
NEW YORK, Nov. 10, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended September 30, 2016.

Financial Results for the Third Quarter of 2016

For the three months ended September 30, 2016, Dipexium reported a net loss of $4.6 million, compared to a net loss of $5.0 million for the three months ended September 30, 2015, a decrease of $0.4 million. The change was primarily due to a $0.5 million decrease in manufacturing relating expenses offset by a $0.1 million increase in Phase 3 clinical trial related expenses.

Read at PR Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES